CLINICAL TRIALS PROFILE FOR LESTAURTINIB

Clinical Trials for Lestaurtinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00079482 ↗	Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)	Completed	Cephalon	Phase 2	The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).
NCT00084422 ↗	N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 1	RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
NCT00084422 ↗	N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma	Completed	New Approaches to Neuroblastoma Therapy Consortium	Phase 1	RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
NCT00469859 ↗	Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lestaurtinib together with cytarabine and idarubicin may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lestaurtinib when given together with cytarabine and idarubicin and to see how well they work in treating younger patients with relapsed or refractory acute myeloid leukemia.
NCT00469859 ↗	Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	Children's Oncology Group	Phase 1/Phase 2	RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lestaurtinib together with cytarabine and idarubicin may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lestaurtinib when given together with cytarabine and idarubicin and to see how well they work in treating younger patients with relapsed or refractory acute myeloid leukemia.
NCT00494585 ↗	CEP-701 for PH-negative Myelofibrosis	Completed	Cephalon	Phase 2	The goal of this clinical research study is to find out if CEP-701 can help control myelofibrosis (MF). The safety of CEP-701 will also be studied.

Clinical Trial Conditions for Lestaurtinib

Condition Name

Condition Name
Intervention	Trials
Leukemia	2
Myelofibrosis	2
Polycythemia Vera	2
Neuroblastoma	1

Condition MeSH

Condition MeSH
Intervention	Trials
Leukemia, Myeloid, Acute	3
Leukemia	3
Polycythemia Vera	2
Polycythemia	2

Clinical Trial Locations for Lestaurtinib

Trials by Country

Trials by Country
Location	Trials
United States	108
Canada	11
Australia	6
New Zealand	2
Israel	1

Trials by US State

Trials by US State
Location	Trials
Pennsylvania	6
New York	6
Maryland	5
California	5
Washington	4

Clinical Trial Progress for Lestaurtinib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	3
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	2
Unknown status	1

Clinical Trial Sponsors for Lestaurtinib

Sponsor Name

Sponsor Name
Sponsor	Trials
National Cancer Institute (NCI)	4
Cephalon	3
Children's Oncology Group	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	7
NIH	4
Industry	3